title: Effects of atropine sulphate on seizure activity and brain damage produced by soman in guinea-pigs: ECoG correlates of neuropathology.
abstract: The present study describes the effects of pyridostigmine (PYR; 0.2 mg/kg) and atropine sulphate (AS; 5 mg/kg) on guinea-pigs intoxicated by a high dose (2xLD50) of the organophosphate compound, soman, an irreversible inhibitor of acetylcholinesterase. The medication was shown to counteract the acute respiratory distress and lethality normally produced by the intoxication. Moreover, due to the central activity of AS, soman-induced electrocorticographic (ECoG) seizure activity was either totally prevented, or reduced in duration and overall intensity. In addition, as established in the 24-hr survivors, seizure-related neuropathology was either prevented, or reduced in topographical extent and severity. An attempt to correlate our electrographic and morphological findings gives evidence that (a), the occurrence of seizure activity is the primary factor necessary for the development of acute neuropathology; (b), the duration of ECoG seizures is a secondary factor, on which the topographical distribution of brain damage finally depends; (c), the minimal duration of seizures necessary to produce 24 hr-damage in the most sensitive areas (e.g. the amygdala) is less than 70 min; (d), the overall intensity/power of epileptiform discharges is a tertiary factor which influences the severity of damage; (e), in addition, ECoG power spectral analysis suggested that an acute increase of relative power in the lower (delta) frequency band might be a real-time external marker of the starting cerebral lesions and is thus predictive for their future installation. All these data confirm the tight relationships which exist between seizure activity and neuropathology in soman poisoning, and suggest that refined, standardized analysis of electrographic parameters drawn from ECoG tracings and power spectrum might serve as a useful tool to predict the presence, localization, and severity of soman-induced brain damage.
authors.affiliation: Centre de Recherches du Service de Santé des Armées, Unité de Neuropharmacologie, La Tronche, France. 100437.201@compuserve.com
authors.forename: P
authors.initials: P
authors.lastname: Carpentier
authors.forename: A
authors.initials: A
authors.lastname: Foquin
authors.forename: G
authors.initials: G
authors.lastname: Rondouin
authors.forename: M
authors.initials: M
authors.lastname: Lerner-Natoli
authors.forename: D M
authors.initials: DM
authors.lastname: de Groot
authors.forename: G
authors.initials: G
authors.lastname: Lallement
mesh_terms: D000818:Animals; D001285:Atropine / Q000627:therapeutic use*; D001921:Brain / Q000473:pathology* / Q000503:physiopathology; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D003292:Convulsants / Q000633:toxicity*; D004569:Electroencephalography / Q000187:drug effects*; D006168:Guinea Pigs; D008297:Male; D018727:Muscarinic Antagonists / Q000627:therapeutic use*; D020258:Neurotoxicity Syndromes / Q000473:pathology / Q000503:physiopathology / Q000517:prevention & control*; D011729:Pyridostigmine Bromide / Q000627:therapeutic use; D012640:Seizures / Q000139:chemically induced / Q000517:prevention & control*; D012999:Soman / Q000633:toxicity*
chemical_list: D002800:Cholinesterase Inhibitors; D003292:Convulsants; D018727:Muscarinic Antagonists; D001285:Atropine; D012999:Soman; D011729:Pyridostigmine Bromide